The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Tauroursodeoxycholate—Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives
Open accessAbstract
Tauroursodeoxycholic acid (TUDCA) is a naturally occurring hydrophilic bile acid that has been used for centuries in Chinese medicine. Chemically, TUDCA is a taurine conjugate of ursodeoxycholic acid (UDCA), which in contemporary pharmacology is approved by Food and Drug Administration (FDA) for treatment of primary biliary cholangitis. Interestingly, numerous recent studies demonstrate that mechanisms of TUDCA functioning extend beyond hepatobiliary disorders. Thus, TUDCA has been demonstrated to display potential therapeutic benefits in various models of many diseases such as diabetes, obesity, and neurodegenerative diseases, mostly due to its cytoprotective effect. The mechanisms underlying this cytoprotective activity have been mainly attributed to alleviation of endoplasmic reticulum (ER) stress and stabilization of the unfolded protein response (UPR), which contributed to naming TUDCA as a chemical chaperone. Apart from that, TUDCA has also been found to reduce oxidative stress, suppress apoptosis, and decrease inflammation in many in-vitro and in-vivo models of various diseases. The latest research suggests that TUDCA can also play a role as an epigenetic modulator and act as therapeutic agent in certain types of cancer. Nevertheless, despite the massive amount of evidence demonstrating positive effects of TUDCA in pre-clinical studies, there are certain limitations restraining its wide use in patients. Here, molecular and cellular modes of action of TUDCA are described and therapeutic opportunities and limitations of this bile acid are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Proteasome inhibitors in cancer therapy
Manasanch, E. E., & Orlowski, R. Z. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.206 · Cited by 1,024
Bile acid signaling in metabolic disease and drug therapy
Li, T., & Chiang, J. Y. L. (2014) · Pharmacological Reviews · doi:10.1124/pr.113.008201 · Cited by 935 · cited 2×
“Finally, UDCA returns to the liver with enterohepatic circulation and is there conjugated with taurine to form TUDCA [5].”
BackgroundPaumgartner, G., & Beuers, U. (2002) · Hepatology · doi:10.1053/jhep.2002.36088 · Cited by 748
Bile acids as regulatory molecules
Hylemon, P. B., Zhou, H., Pandak, W. M., Ren, S., Gil, G., & Dent, P. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r900007-jlr200 · Cited by 694 · cited 1×
“Since TUDCA is effectively metabolized by the liver and only minimal splanchnic escape of bile acid conjugates into the systemic circulation, it is likely that a difference in route of administration may further limit the systemic availability of TUDCA in humans [195].”
BackgroundShiba-Fukushima, K., Imai, Y., Yoshida, S., Ishihama, Y., Kanao, T., Sato, S., & Hattori, N. (2012) · Scientific Reports · doi:10.1038/srep01002 · Cited by 577
Boden, G., Duan, X., Homko, C., Molina, E. J., Song, W., Perez, O., Cheung, P., & Merali, S. (2008) · Diabetes · doi:10.2337/db08-0604 · Cited by 468
Drug Insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis
Beuers, U. (2006) · Nature Clinical Practice Gastroenterology & Hepatology · doi:10.1038/ncpgasthep0521 · Cited by 417
The western diet and lifestyle and diseases of civilization
Carrera-Bastos, P., Fontes, O'Keefe, Lindeberg, & Cordain (2011) · Research Reports in Clinical Cardiology · doi:10.2147/rrcc.s16919 · Cited by 342
A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
Schoemaker, M. H., de la Rosa, L. C., Buist-Homan, M., Vrenken, T. E., Havinga, R., Poelstra, K., Haisma, H. J., Jansen, P. L. M., & Moshage, H. (2004) · Hepatology · doi:10.1002/hep.20246 · Cited by 229 · cited 1×
“Indeed, activation of anti-apoptotic nuclear transcription factor (NFκB) [40], stimulation of mitogen-activated protein kinase (MAPK)- and phosphatidylinositol 3-kinase (PI3K)-dependent pathways [29,41], or initiation of Akt signaling cascade [42], have already been demonstrated.”
BackgroundThe biosynthesis, signaling, and neurological functions of bile acids
Kiriyama, Y., & Nochi, H. (2019) · Biomolecules · doi:10.3390/biom9060232 · Cited by 204
Effects of bile acids on neurological function and disease
McMillin, M., & DeMorrow, S. (2016) · The FASEB Journal · doi:10.1096/fj.201600275r · Cited by 192
Nunes, A. F., Amaral, J. D., Lo, A. C., Fonseca, M. B., Viana, R. J. S., Callaerts-Vegh, Z., D’Hooge, R., & Rodrigues, C. M. P. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8256-y · Cited by 192
Castro-Caldas, M., Carvalho, A. N., Rodrigues, E., Henderson, C. J., Wolf, C. R., Rodrigues, C. M. P., & Gama, M. J. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8295-4 · Cited by 156 · cited 8×
“In experimental conditions, TUDCA reduced TNFα and IFN-γ-induced up-regulation of pro-inflammatory markers such as TNF-α, IL-1β, and IL-6, and alleviated NF-κB activation [164].”
BackgroundInfluentialCullen, S. N., Rust, C., Fleming, K., Edwards, C., Beuers, U., & Chapman, R. W. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.12.023 · Cited by 136
Lo, A. C., Callaerts-Vegh, Z., Nunes, A. F., Rodrigues, C. M. P., & D'Hooge, R. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2012.09.003 · Cited by 120
Nrf2 activation by tauroursodeoxycholic acid in experimental models of Parkinson's disease
Moreira, S., Fonseca, I., Nunes, M. J., Rosa, A., Lemos, L., Rodrigues, E., Carvalho, A. N., Outeiro, T. F., Rodrigues, C. M. P., Gama, M. J., et al. (2017) · Experimental Neurology · doi:10.1016/j.expneurol.2017.05.009 · Cited by 112
Vettorazzi, J. F., Ribeiro, R. A., Borck, P. C., Branco, R. C. S., Soriano, S., Merino, B., Boschero, A. C., Nadal, A., Quesada, I., & Carneiro, E. M. (2016) · Metabolism · doi:10.1016/j.metabol.2015.10.021 · Cited by 104 · cited 2×
“This suggested that TUDCA enhances GSIS in pancreatic β-cells likely by activating the TGR5 receptor and initiating the cAMP/PKA pathway [113].”
BackgroundYanguas-Casás, N., Barreda-Manso, M. A., Nieto-Sampedro, M., & Romero-Ramírez, L. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-50 · Cited by 103
Tauroursodeoxycholic acid improves motor symptoms in a mouse model of Parkinson's disease
Rosa, A. I., Duarte-Silva, S., Silva-Fernandes, A., Nunes, M. J., Carvalho, A. N., Rodrigues, E., Gama, M. J., Rodrigues, C. M. P., Maciel, P., & Castro-Caldas, M. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1062-4 · Cited by 94
Rosa, A. I., Fonseca, I., Nunes, M. J., Moreira, S., Rodrigues, E., Carvalho, A. N., Rodrigues, C. M. P., Gama, M. J., & Castro-Caldas, M. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2017.06.004 · Cited by 82
α5β1-integrins are sensors for tauroursodeoxycholic acid in hepatocytes
Gohlke, H., Schmitz, B., Sommerfeld, A., Reinehr, R., & Häussinger, D. (2013) · Hepatology · doi:10.1002/hep.25992 · Cited by 77
Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease
Graham, S. F., Rey, N. L., Ugur, Z., Yilmaz, A., Sherman, E., Maddens, M., Bahado-Singh, R. O., Becker, K., Schulz, E., Meyerdirk, L. K., et al. (2018) · Metabolites · doi:10.3390/metabo8040071 · Cited by 60
Kim, S. J., Ko, W.-K., Jo, M.-J., Arai, Y., Choi, H., Kumar, H., Han, I.-B., & Sohn, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-21621-5 · Cited by 59
Treatment of primary biliary cholangitis ursodeoxycholic acid non‐responders: A systematic review
Suraweera, D., Rahal, H., Jimenez, M., Viramontes, M., Choi, G., & Saab, S. (2017) · Liver International · doi:10.1111/liv.13477 · Cited by 38 · cited 1×
“Furthermore, UDCA presented good efficacy in improvement of the outcome of primary biliary cholangitis mostly due to increased hydrophilicity of the biliary bile acid pool [56,57].”
Backgroundβ1 integrin is a long-sought sensor for tauroursodeoxycholic acid
Beuers, U. (2013) · Hepatology · doi:10.1002/hep.26228 · Cited by 9
Cited by
Trial of Sodium Phenylbutyrate–Taurursodiol for Amyotrophic Lateral Sclerosis
Paganoni, S., Macklin, E. A., Hendrix, S., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., Owegi, M. A., Quick, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1916945 · Cited by 536
Pharmacological targeting of endoplasmic reticulum stress in disease
Marciniak, S. J., Chambers, J. E., & Ron, D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00320-3 · Cited by 520
Zhang, D., Liu, Y., Zhu, Y., Zhang, Q., Guan, H., Liu, S., Chen, S., Mei, C., Chen, C., Liao, Z., et al. (2022) · Nature Cell Biology · doi:10.1038/s41556-022-00894-z · Cited by 285
Paganoni, S., Hendrix, S., Dickson, S. P., Knowlton, N., Macklin, E. A., Berry, J. D., Elliott, M. A., Maiser, S., Karam, C., Caress, J. B., et al. (2021) · Muscle & Nerve · doi:10.1002/mus.27091 · Cited by 180
Chen, Y.-K., Liu, T.-T., Teia, F. K. F., & Xie, M.-Z. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1218880 · Cited by 74
Metadata
- Authors
- Kusaczuk, M.
- Venue
- Cells
- Publisher
- MDPI AG
- Published
- 2019-11-20
- Volume
- 8
- Issue
- 12
- Pages
- 1471
- ISSN
- 2073-4409 (ISSN-L)
- OpenAlex
- W2989741665
- Cited by
- 236
- References
- 26
- FWCI
- 8.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.